Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. GlaxoSmithKline Plc. News release: GSK receives European marketing authorization for self-injectable formulation of Benlysta for the treatment of systemic lupus erythematosus. 2017 Nov 13.
  2. U.S. Food and Drug Administration. Safety alert: Febuxostat (brand name Uloric): Drug safety communication—FDA to evaluate increased risk of heart-related death. 2017 Nov 15.

Related Articles

    FAST Results for Febuxostat Safety in Patients with Gout

    ACR CONVERGENCE 2020—The results of a post-authorization study comparing the cardiovascular safety of febuxostat vs. allopurinol were presented in a late-breaking abstract session at the ACR’s fully virtual annual meeting on Monday, Nov. 9. Cardiologist Thomas MacDonald, MD, FRCP, MBChB, clinical professor (teaching and research) of molecular and clinical medicine, University of Dundee School of…

    New Study Raises Cardiovascular Questions about Febuxostat for Gout

    New research raises questions about the cardiovascular safety of febuxostat for gout patients compared with allopurinol. The study found that although febuxostat was noninferior to allopurinol, febuxostat-treated patients had similar overall rates of major adverse cardiovascular events as allopurinol-treated patients, but had higher rates of all-cause mortality and cardiovascular mortality…